soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Editorial Fellow Harleen Marwah, MD, summarizes the trial. Read the full at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM Oral semaglutide reduces heart risks
Description
Caution is advised if you have congenital long QT syndrome or are on medications that affect heart rhythm, because azithromycin can add to that risk
Research-grade lyophilized peptide
Note: Anti-obesity GLP-1 includes Wegovy and Zepbound
Researchers really don't really know
Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression
What is included
